1. index cases and treatment-eligible household contacts: * inability to take medications orally or injected * known sensitivity/allergy to interferons or use of interferons for another indication * known adverse drug-drug interactions with any study drugs * malignancy * known clinical immune deficiency * pregnancy or unwillingness, of female participants of childbearing potential to use recognised methods of birth control/contraception during the trial period, * retinopathy, * known grade 4 or 5 chronic kidney or liver disease, * known arrhythmias, * known autoimmune diseases or chronic inflammatory disease, * chronic liver disease, * hospitalisation for depression in the last 3 months, * current suicidal ideation, * previous therapeutic use of ifn 2. all subjects: * declined participation, * the index case has been in complete self-quarantine from other household members during the 48 hours prior to diagnosis of sars-cov-2 infection.

1. index cases and treatment-eligible household contacts: * inability to take medications orally or injected * known sensitivity/allergy to interferons or use of interferons for another indication * known adverse drug-drug interactions with any study drugs * malignancy * known clinical immune deficiency * pregnancy or unwillingness, of female participants of childbearing potential to use recognised methods of birth control/contraception during the trial period, * retinopathy, * known grade 4 or 5 chronic kidney or liver disease, * known arrhythmias, * known autoimmune diseases or chronic inflammatory disease, * chronic liver disease, * hospitalisation for depression in the last 3 months, * current suicidal ideation, * previous therapeutic use of ifn 2. all subjects: * declined participation, * the index case has been in complete self-quarantine from other household members during the 48 hours prior to diagnosis of sars-cov-2 infection.

index cases and treatment-eligible household contacts: inability to take medications orally or injected known sensitivity/allergy to interferons or use of interferons for another indication known adverse drug-drug interactions with any study drugs malignancy known clinical immune deficiency pregnancy or unwillingness, of female participants of childbearing potential to use recognised methods of birth control/contraception during the trial period, retinopathy, known grade 4 or 5 chronic kidney or liver disease, known arrhythmias, known autoimmune diseases or chronic inflammatory disease, chronic liver disease, hospitalisation for depression in the last 3 months, current suicidal ideation, previous therapeutic use of ifn all subjects: declined participation, the index case has been in complete self-quarantine from other household members during the 48 hours prior to diagnosis of sars-cov-2 infection.

index cases and treatment-eligible household contacts: inability to take medications orally or injected known sensitivity/allergy to interferons or use of interferons for another indication known adverse drug-drug interactions with any study drugs malignancy known clinical immune deficiency pregnancy or unwillingness, of female participants of childbearing potential to use recognised methods of birth control/contraception during the trial period, retinopathy, known grade 4 or 5 chronic kidney or liver disease, known arrhythmias, known autoimmune diseases or chronic inflammatory disease, chronic liver disease, hospitalisation for depression in the last 3 months, current suicidal ideation, previous therapeutic use of ifn all subjects: declined participation, the index case has been in complete self-quarantine from other household members during the 48 hours prior to diagnosis of sars-cov-2 infection.

1. index cases and treatment-eligible household contacts: - inability to take medications orally or injected - known sensitivity/allergy to interferons or use of interferons for another indication - known adverse drug-drug interactions with any study drugs - malignancy - known clinical immune deficiency - pregnancy or unwillingness, of female participants of childbearing potential to use recognised methods of birth control/contraception during the trial period, - retinopathy, - known grade 4 or 5 chronic kidney or liver disease, - known arrhythmias, - known autoimmune diseases or chronic inflammatory disease, - chronic liver disease, - hospitalisation for depression in the last 3 months, - current suicidal ideation, - previous therapeutic use of ifn 2. all subjects: - declined participation, - the index case has been in complete self-quarantine from other household members during the 48 hours prior to diagnosis of sars-cov-2 infection.

1. index cases and treatment-eligible household contacts: - inability to take medications orally or injected - known sensitivity/allergy to interferons or use of interferons for another indication - known adverse drug-drug interactions with any study drugs - malignancy - known clinical immune deficiency - pregnancy or unwillingness, of female participants of childbearing potential to use recognised methods of birth control/contraception during the trial period, - retinopathy, - known grade 4 or 5 chronic kidney or liver disease, - known arrhythmias, - known autoimmune diseases or chronic inflammatory disease, - chronic liver disease, - hospitalisation for depression in the last 3 months, - current suicidal ideation, - previous therapeutic use of ifn 2. all subjects: - declined participation, - the index case has been in complete self-quarantine from other household members during the 48 hours prior to diagnosis of sars-cov-2 infection.